Filing Details
- Accession Number:
- 0000950170-25-004870
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-01-13 16:34:40
- Reporting Period:
- 2025-01-08
- Accepted Time:
- 2025-01-13 16:34:40
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1750284 | Olema Pharmaceuticals Inc. | OLMA | () | DE |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1703031 | Bain Capital Life Sciences Investors, Llc | 200 Clarendon Street Boston MA 02116 | No | No | No | No | |
| 1996931 | Bain Capital Life Sciences Iv General Partner, Llc | 200 Clarendon Street Boston MA 02116 | No | No | No | No | |
| 1996979 | Bain Capital Life Sciences Fund Iv, L.p. | 200 Clarendon Street Boston MA 02116 | No | No | No | No | |
| 2015553 | Bain Capital Life Sciences Opportunities Iv, L.p. | 200 Clarendon Street Boston MA 02116 | No | No | No | No | |
| 2015657 | Bain Capital Life Sciences Opportunities Iv Gp, Llc | 200 Clarendon Street Boston MA 02116 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-01-08 | 300,000 | $5.76 | 7,800,000 | No | 4 | P | Indirect | See footnotes |
| Common Stock | Disposition | 2025-01-10 | 3,500,000 | $0.00 | 4,300,000 | No | 4 | J | Indirect | See footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See footnotes |
| No | 4 | J | Indirect | See footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Pre-Funded Warrant (right to buy) | Acquisiton | 2025-01-10 | 3,500,000 | $0.00 | 3,500,000 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 3,500,000 | 2025-01-13 | No | 4 | J | Indirect |
Footnotes
- Represents securities held directly by Bain Capital Life Sciences Opportunities IV, L.P. ("BCLS Opportunities IV").
- Bain Capital Life Sciences Investors, LLC ("BCLSI") is the manager of Bain Capital Life Sciences IV General Partner, LLC ("BCLS Fund IV GP"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. ("BCLS Fund IV"), which is the sole member of Bain Capital Life Sciences Opportunities IV GP, LLC ("BCLS Opportunities IV GP" and, together with BCLSI, BCLS Fund IV GP, BCLS Fund IV, BCLS Opportunities IV GP and BCLS Opportunities IV, the "Bain Capital Life Sciences Entities"), which is the general partner of BCLS Opportunities IV. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Opportunities IV. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Opportunities IV GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
- The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.44 to $5.92, inclusive. The reporting persons undertake to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- On January 10, 2025, BCLS Opportunities IV entered into an exchange agreement with the Issuer pursuant to which BCLS Opportunities IV exchanged 3,500,000 shares of Common Stock for a pre-funded warrant to purchase 3,500,000 shares of common stock in reliance on the exemption from registration contained in Section 3(a)(9) of the Securities Act of 1933, as amended. The exchange transaction did not result in any change in the Bain Capital Life Sciences Entities pecuniary interest in the subject equity securities.
- BCLS Opportunities IV is prohibited from exercising this pre-funded warrant if the Bain Capital Life Sciences Entities would, in the aggregate, beneficially own more than 9.99% of the total number of shares of common stock then issued and outstanding immediately after giving effect to such exercise.
- The pre-funded warrant does not expire.
Billionaire Hedge Funds
